Diagnostic Testing & Technology Report

A new laboratory-developed test (LDT) from Quest Diagnostics (Madison, N.J.) can assist physicians in determining whether a patient with a history of HIV drug resistance will respond to the class of antiretroviral therapies known as CCR5 antagonist entry inhibitors. Launched on June 12, Quest’s HIV-1 Coreceptor Tropism Test will compete with the market-leading Trofile assay developed and performed by Monogram Biosciences (South San Francisco, Calif.). The new LDT replaces SensiTrop, the HIV tropism test that…